These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21503604)

  • 21. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
    Hodé Y; Benyamina A; Arbus C; Reimold M
    Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calculating occupancy when one does not have baseline: a comparison of different options.
    Kim E; Howes OD; Yu KS; Jeong JM; Lee JS; Jang IJ; Shin SG; Kapur S; Kwon JS
    J Cereb Blood Flow Metab; 2011 Aug; 31(8):1760-7. PubMed ID: 21522162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
    Kapur S; Zipursky R; Jones C; Remington G; Houle S
    Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.
    Wong DF; Kuwabara H; Brašić JR; Stock T; Maini A; Gean EG; Loebel A
    Psychopharmacology (Berl); 2013 Sep; 229(2):245-52. PubMed ID: 23649882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
    Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
    Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
    Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
    Kitamura A; Takagaki T; Nemoto D; Tomita Y; Nishibe H; Kakuyama H
    J Clin Pharmacol; 2021 Aug; 61(8):1069-1080. PubMed ID: 33599975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.